In vivo 2D mapping of impaired murine cardiac energetics in NO-induced heart failure

Magnetic Resonance in Medicine

Volumn 57, Issue 1, 2007, Pages 50-58

  Flögel, Ulrich ^a   Jacoby, Christoph ^a   Gödecke, Axel ^a   Schrader, Jürgen ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Energy metabolism; Heart failure; Magnetic resonance imaging; Magnetic resonance spectroscopy; Nitric oxide

Indexed keywords

CARDIOLOGY; CHEMICAL SHIFT; IMAGE RESOLUTION; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; METABOLISM; NITRIC OXIDE; PHOSPHATES;

CAUSE-AND-EFFECT RELATIONSHIPS; CHEMICAL SHIFT IMAGING; ENERGY METABOLISM; FUTURE APPLICATIONS; HEART FAILURE; HIGH ENERGY PHOSPHATES; HIGH SPATIAL RESOLUTION; INDUCIBLE NITRIC OXIDE SYNTHASE (INOS);

HEART;

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PERCHLORIC ACID; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CYTOSOL; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; ENERGY METABOLISM; ENERGY TRANSFER; GENE OVEREXPRESSION; HEART FAILURE; HEART VENTRICLE SEPTUM; HIGH ENERGY PHOSPHATE; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; THORAX; TIME PERCEPTION; TRANSGENIC MOUSE;

EID: 33846043075     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21101     Document Type: Article

References (36)

1. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 1990;323:1593-1600.
2. 31P NMR spectroscopy of the human heart at 4 T: detection of substantially uncontaminated cardiac spectra and differentiation of subepicardium and subendocardium. Magn Reson Med 1992;26:368-376.
3. 31P spectroscopic imaging of the human heart at 4.1 T. Magn Reson Med 1995;33:427-431.
4. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatineto-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96:2190-2196.
5. 31P magnetic resonance spectroscopy during handgrip exercise. Circulation 1994;89:1709-1716.
6. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991;122:795-801.
7. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992;86:1810-1818.
8. Olson RE, Schwartz WB. Myocardial metabolism in congestive heart failure. Medicine 1951;30:21-41.
9. Olson RE. Myocardial metabolism in congestive heart failure. J Chronic Dis 1959;9:442-464.
10. de Belder AJ, Radomski MW, Why HJ, Richardson PJ, Bucknall CA, Salas E, Martin JF, Moncada S. Nitric oxide synthase activities in human myocardium. Lancet 1993;341:84-85.
11. Haywood GA, Tsao PS, der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, Lewis NP, Byrne CD, Rickenbacher PR, Bishopric NH, Cooke JP, McKenna WJ, Fowler MB. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-1094.
12. Chen Y, Traverse JH, Du R, Hou M, Bache RJ. Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation 2002;106:273-279.
13. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 2002;105:236-243.
14. Stein B, Eschenhagen T, Rüdiger J, Scholz H, Förstermann U, Gath I. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure. J Am Coll Cardiol 1998;32:1179-1186.
15. Shiva S, Oh JY, Landar AL, Ulasova E, Venkatraman A, Bailey SM, Darley-Usmar VM. Nitroxia: the pathological consequence of dysfunction in the nitric oxide-cytochrome c oxidase signaling pathway. Free Radic Biol Med 2005;38:297-306.
16. Saupe KW, Spindler M, Tian R, Ingwall JS. Impaired cardiac energetics in mice lacking muscle-specific isoenzymes of creatine kinase. Circ Res 1998;82:898-907.
17. Flögel U, Decking UK, Gödecke A, Schrader J. Contribution of NO to ischemia-reperfusion injury in the saline-perfused heart: a study in endothelial NO synthase knockout mice. J Mol Cell Cardiol 1999;31:827-836.
18. Omerovic E, Basetti M, Bollano E, Bohlooly M, Tornell J, Isgaard J, Hjalmarson A, Soussi B, Waagstein F. In vivo metabolic imaging of cardiac bioenergetics in transgenic mice. Biochem Biophys Res Commun 2000;271:222-228.
19. Chacko VP, Aresta F, Chacko SM, Weiss RG. MRI/MRS assessment of in vivo murine cardiac metabolism, morphology, and function at physiological heart rates. Am J Physiol Heart Circ Physiol 2000;279:H2218-H2224.
20. Gödecke A, Molojavyi A, Heger J, Flögel U, Ding Z, Jacoby C, Schrader J. Myoglobin protects the heart from inducible nitric-oxide synthase (iNOS)-mediated nitrosative stress. J Biol Chem 2003;278:21761-21766.
21. Heger J, Gödecke A, Flögel U, Merx MW, Molojavyi A, Kühn-Velten WN, Schrader J. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 2002;90:93-99.
22. Gödecke A, Flögel U, Zanger K, Ding Z, Hirchenhain J, Decking UK, Schrader J. Disruption of myoglobin in mice induces multiple compensatory mechanisms. Proc Natl Acad Sci U S A 1999;96:10495-10500.
23. Flögel U, Laussmann T, Gödecke A, Abanador N, Schäfers M, Fingas CD, Metzger S, Levkau B, Jacoby C, Schrader J. Lack of myoglobin causes a switch in cardiac substrate selection. Circ Res 2005;96:e68-e75.
24. Jacoby C, Molojavyi A, Flögel U, Merx MW, Ding Z, Schrader J. Direct comparison of magnetic resonance imaging and conductance microcatheter in the evaluation of left ventricular function in mice. Basic Res Cardiol 2006;101:87-95.
25. Pohmann R, von Kienlin M. Accurate phosphorus metabolite images of the human heart by 3D acquisition-weighted CSI. Magn Reson Med 2001;45:817-826.
26. Bottomley PA, Hardy CJ, Roemer PB. Phosphate metabolite imaging and concentration measurements in human heart by nuclear magnetic resonance. Magn Reson Med 1990;14:425-434.
27. 31P NMR spectra for partial saturation. Evidence that saturation factors for PCr/ATP are homogeneous in normal and disease states. J Magn Reson 1991;95:341-355.
28. Friedrich J, Nascimben L, Liao R, Ingwall JS. Phosphocreatine T1 measurements with and without exchange in the heart. Magn Reson Med 1993;30:45-50.
29. 13C NMR spectroscopy. NMR Biomed 1997;10:50-58.
30. 31P magnetic resonance spectroscopy. Circulation 1995;92:15-23.
31. Wunderlich C, Flögel U, Gödecke A, Heger J, Schrader J. Acute inhibition of myoglobin impairs contractility and energy state of iNOS-overexpressing hearts. Circ Res 2003;92:1352-1358.
32. Giuffre A, Sarti P, D'Itri E, Buse G, Soulimane T, Brunori M. On the mechanism of inhibition of cytochrome c oxidase by nitric oxide. J Biol Chem 1996;271:33404-33408.
33. Flögel U, Merx MW, Gödecke A, Decking UK, Schrader J. Myoglobin: a scavenger of bioactive NO. Proc Natl Acad Sci USA 2001;98:735-740.
34. Conway MA, Bottomley PA, Ouwerkerk R, Radda GK, Rajagopalan B. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation 1998;97:1716-1723.
35. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998;97:2536-2542.
36. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004;95:135-145.